References
- Lachmann P J, Pangburn M K, Oldroy R G. Breakdown of C3 after complement activation. Identification of new fragments, C3g, using monoclonal antibodies. J Exp Med 1982; 156: 205–16
- Brandslund I. Development and clinical application of electroimmunoassays for direct quantification of the complement C3d split products, C3c, and C3d. Scand J Clin Lab Invest 1984; 168: 57–73
- Moines T E. Quantification of the C3d split products of human complement by a sensitive enzyme-linked immunosorbent assay. Science 1985; 21: 607–13
- Vergani D, Bevis I, Nasaruddin B A, Mieli-Vergani G, Tee D EH. Clinical application of a new nephelometric technique to measure complement activation. J Clin Pathol 1983; 36: 793–7
- Wagner J L, Hugh T E. Radioimmunoassay for anaphylatoxin: a sensitive method for determining complement activation products in biological fluids. Anal Biochem 1984; 136: 75–88
- Holmsgaard-Nielsen U, Jensenius J C, Teisner B, Erb K. Measurement of C3 conversion by elisa estimation of neodeterminants on the C3d moiety. J Immunol Met 1986; 94: 1–6
- Garred P, Mollness T E, Lea T. Quantification in enzyme-linked immunosorbent assay of a C3 neoepitope expressed on activated human complement factor C3. Scand J Immunol 1988; 27: 329–35
- Knudsen J, Nielsen A H, Pedersen J O, Jersil C. Activation of complement, generation of C5a, leukopenia and hypoxemia: interlinked membrane-dependent events during hemodialysis. Blood Purif 1984; 2: 98–107
- Dorner R W, Alexander R L, Moore T L. Rheumatoid Factors. Clin Chim Acta 1987; 167: 1–21
- Brandslund I, Peters N D, Estrup L. Steroids reduce complement activation in rheumatoid arthritis. Int J Tiss React 1985; 7: 161–5